24/7 BIOPHARMA - issue 1 / October 2024

NEWS

demonstrating our reliability and dedication to the industry. The life science industry is experiencing rapid growth, driven by technological advancements and a rising demand for innovative treatments. However, the global supply chain for these therapies faces challenges, including limited manufacturing capacity and complex regulatory requirements. SK

pharmteco’s new facility addresses these challenges by providing a scalable and reliable solution for producing these critical therapies. “Our new facility represents a significant investment in our future and a commitment to delivering exceptional value to our customers,” said Yongwoo Park, SK pharmteco’s President, Small Molecule, Asia. “By expanding our capacity and

capabilities, we can offer even faster turnaround times, increased flexibility, and a higher level of quality. This investment further solidifies SK pharmteco’s position as a trusted partner for companies developing innovative cell and gene therapies and small molecules, enabling us to accelerate the development and commercialization of life-changing treatments.”

CPHI WW, Olon will attend with a stronger market position after the two international

acquisitions On the occasion of the main international event dedicated to the pharmaceutical industry, open-ing on October 8th in Milan, home of its HQ, Olon, the Italian Group recognized as world leader in the development and production of APIs, confirms its participation (stand Hall 1 Booth B2). This year, Olon presents itself with an even stronger market position following two significant acquisi-tions that have expanded both its service offerings and production capacity. During the last quar-ter, in fact, Olon announced the acquisition of the French company GTP Bioways, an expert con-tract development and manufacturing organization (CDMO) specialised in process development and manufacturing of antibodies, proteins, bioconjugates and nanodrugs and of HuvePharma Italia Srl and its site of Garessio, (Cuneo, Italy). Huvepharma Italia Srl, with its plant in Garessio, is en-gaged in the development, industrialization, chemical synthesis and manufacturing of active phar-maceutical ingredients, as well as advanced intermediates for the pharmaceutical industry. With these latest acquisitions, Olon now operates a total of fourteen manufacturing plants across the

globe, with an impressive reaction capacity of 3,250 cubic meters and a fermentation capacity of 5,000 cubic meters. In terms of geographical presence, the scale of its manufacturing network, and its installed production volume, Olon has emerged as one of the most significant industrial players both in Italy and across Europe. Spanning three continents, Olon’s 14 state-of-the-art facilities offer highly diversified capabilities, in cluding chemical synthesis, microbial fermentation, mammalian cell culture, bioconjugation, and Fill & Finish (F&F) processes. This extensive and versatile infrastructure reinforces Olon’s position as a global leader in pharmaceutical manufacturing, ensuring the ability to meet a wide range of client needs with precision and excellence.

services for biologics, antibody-drug conjugates and nanodrugs. With cutting-edge facilities located in France, GTP Bioways can support biopharma companies from preclinical to commercial production of their innovative therapies. GTP Bioways’s services are seamlessly integrated with those of Olon. This integration enables Olon to expand and diversify its technological offerings, supporting every stage of the lifecycle, from R&D and preclinical phases to commercial production, through microbial and mammalian fermentation. Additionally, Olon will provide comprehensive services for the development and production of innovative ADC classes, offering a complete solution from mAbs to linkers, payloads, conjugation, and fill-and-finish.

GTP Bioways is a customer-centric and science driven CDMO committed to offering uniquely custom ised process development and GMP manufacturing

76 TWENTYFOURSEVENBIOPHARMA Issue 1 / October 2024